Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the quarter and six month period ended June 30, 2008 and provided an update on the Company's progress with its product development candidates. The net loss for the quarter and six month period ended June 30, 2008, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $14.1 million and $28.7 million, respectively, compared to a net loss of $10.3 million and $21.2 million in the comparable periods in 2007. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at June 30, 2008 of $95.3 million.

"Alexza continues to make significant progress with our lead program, AZ-004 (Staccato(R) loxapine), which is being developed for the treatment of acute agitation in schizophrenic or bipolar disorder patients," said Thomas B. King, President and CEO of Alexza. "During the first seven months of 2008, we initiated and completed the dosing of our first AZ-004 Phase 3 clinical trial, and have initiated dosing of our second AZ-004 Phase 3 clinical trial. In addition, we had clinical readouts from clinical trials with AZ-104, AZ-007 and AZ-002. We are also scaling up our manufacturing, quality systems, regulatory affairs and commercial operations as we prepare for the future commercialization of AZ-004."

Financial Results - Periods Ended June 30, 2008 and 2007

GAAP operating expenses were $20.5 million and $39.7 million in the quarter and six month period ended June 30, 2008, compared to $14.2 million and $28.0 million for the comparable periods in 2007. The increases resulted primaril
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... PRNewswire / -- Life Technologies Corporation ... OneTouch System, an automated sample preparation system for the Ion Personal ... to five minutes and offers walk-away convenience. Ion Torrent is ... $5,000; the first shipments will be in late June and ...
... Marinus Pharmaceuticals, Inc., the leader in the development ... the award of a $3 million grant by the ... ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone ... neurosteroid receptor. Early research suggests that normalizing neurosteroid levels ...
Cached Medicine Technology:Life Technologies Announces an Automated Sample Preparation System for its Ion PGM™ Sequencer 2Life Technologies Announces an Automated Sample Preparation System for its Ion PGM™ Sequencer 3Life Technologies Announces an Automated Sample Preparation System for its Ion PGM™ Sequencer 4Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... part of its new initiative, Expanding Access to Opioid Substitution ... and Central Asia (EECA), the International AIDS Society (IAS) will ... partnership with the Ukrainian Institute on Public Health Policy (UIPHP). ... IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), ...
... Scientists from the Hebrew University have identified the molecular basis ... of this research have just been published in the journal ... entire genetic information required for building the proteins of the ... changes in the cell function. These changes can lead to ...
... compiled by the Commission for the Investigation of Health ... Senate Commission of the Deutsche Forschungsgemeinschaft (DFG, German Research ... dust for the alveolar fraction in light of recent ... thresholds are exceeded. In addition, classifications for uranium and ...
... Mozes HealthDay Reporter , MONDAY, July 18 ... powerful antiretroviral therapies have radically improved the life expectancy ... Now, research suggests that when made affordable and accessible, ... patients. The finding stems from a Canadian research ...
... Over half of all Alzheimer,s disease cases could potentially ... of chronic medical conditions, according to a study led ... the San Francisco VA Medical Center. Analyzing data ... of participants, Barnes concluded that worldwide, the biggest modifiable ...
... memory triggering another, but explanations for that phenomenon have ... the first neurobiological evidence that memories formed in the ... of episodic memory. The research was conducted by ... the School of Arts and Sciences and graduate student ...
Cached Medicine News:Health News:International AIDS Society to launch Virtual Media Centre in July to support opioid substitution therapy in Eastern Europe and Central Asia 2Health News:International AIDS Society to launch Virtual Media Centre in July to support opioid substitution therapy in Eastern Europe and Central Asia 3Health News:International AIDS Society to launch Virtual Media Centre in July to support opioid substitution therapy in Eastern Europe and Central Asia 4Health News:Hebrew U. scientists identify molecular basis for DNA breakage 2Health News:New threshold values for fine particulates at the workplace 2Health News:New threshold values for fine particulates at the workplace 3Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 2Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 3Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 4Health News:Over half of Alzheimer's cases may be preventable, say researchers 2Health News:Penn researchers find neural signature of 'mental time travel' 2
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
The family of Passive Plus DX passive-fixation leads features a 5 mm tip, designed to increase current density and pacing impedance, and a tine fixation, offering versatility and security in lead pla...
... The IsoFlex S lead's small ... ease implantation and lower the ... smaller, more tortuous vessels. Atrial ... and fixation options combine to ...
Unipolar Atrial "J" Lead...
Medicine Products: